<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03400267</url>
  </required_header>
  <id_info>
    <org_study_id>ON-TIME 3</org_study_id>
    <nct_id>NCT03400267</nct_id>
  </id_info>
  <brief_title>The Effect of Opioids on P2Y12 Receptor Inhibition in Patients With ST-Elevation Myocardial Infarction Who Are Pre-treated With Crushed Ticagrelor</brief_title>
  <acronym>ON-TIME 3</acronym>
  <official_title>The Effect of Opioids on P2Y12 Receptor Inhibition in Patients With ST-Elevation Myocardial Infarction Who Are Pre-treated With Crushed Ticagrelor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>A.H. Tavenier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Isala</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Isala</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fast and accurate platelet inhibition is an important therapeutic goal in the acute treatment&#xD;
      of patients with ST-segment elevation myocardial infarction (STEMI). Platelet inhibitory&#xD;
      effects induced by normal oral P2Y12 receptor antagonists, for example ticagrelor, are&#xD;
      delayed in STEMI patients undergoing primary percutaneous coronary intervention (primary&#xD;
      PCI), which may be attributed to impaired absorption affecting drug pharmacokinetics (PK) and&#xD;
      pharmacodynamics (PD). Another therapeutic goal in the acute treatment of STEMI is reduction&#xD;
      of sympathetic stress and catecholamine release, thereby improving the balance between the&#xD;
      demand for and supply of oxygen, by analgesia like fentanyl of morphine. To date, there are&#xD;
      no studies that have specifically assessed the pharmacodynamics influences of fentanyl on&#xD;
      platelet inhibition in STEMI patients who are pre-treated with crushed ticagrelor tablets.&#xD;
      Therefore, In the ON-TIME-3 study, the investigators seek to show the influence of fentanyl&#xD;
      on platelet inhibition in STEMI patients who are pre-treated with crushed ticagrelor in the&#xD;
      ambulance.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 16, 2018</start_date>
  <completion_date type="Actual">November 22, 2019</completion_date>
  <primary_completion_date type="Actual">October 22, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized controlled trial, with randomization to either paracetamol intravenously or fentanyl.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>platelet reactivity</measure>
    <time_frame>directly post-PCI or 1 hour post-angiography</time_frame>
    <description>Platelet reactivity units (PRU) directly post-PCI or 1 hour post-angiography</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>STEMI</condition>
  <condition>STEMI - ST Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>paracetamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fentanyl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <description>Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.</description>
    <arm_group_label>paracetamol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.</description>
    <arm_group_label>fentanyl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        i. age ≥18 years&#xD;
&#xD;
        ii. referred by ambulance paramedics to Isala (Zwolle) or Zuyderland Hospital (Heerlen)&#xD;
&#xD;
        iii. diagnosed in the ambulance with STEMI defined as:&#xD;
&#xD;
          1. ongoing chest pain &gt;30 minutes and &lt;12 hours duration and&#xD;
&#xD;
          2. ST-segment elevation &gt;0.1 milliVolt in at least 2 contiguous leads&#xD;
&#xD;
        iv. ongoing chest pain with a pain score (NRS) ≥4&#xD;
&#xD;
        v. the patient has been informed of the nature of the study, agrees to its provisions and&#xD;
        has provided verbal informed consent in the pre-hospital phase followed by written informed&#xD;
        consent in hospital&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        i. presenting with cardiogenic shock; defined as:&#xD;
&#xD;
          1. systolic blood pressure &lt;90 mmHg and&#xD;
&#xD;
          2. heart rate &gt;100/min and&#xD;
&#xD;
          3. peripheral oxygen saturation &lt;90% (without oxygen administration)&#xD;
&#xD;
        ii. patients with a nasogastric tube in situ or requiring a nasogastric tube&#xD;
&#xD;
        iii. patients who already received fentanyl or paracetamol &lt;2 hours prior to randomization&#xD;
&#xD;
        iv. patients on current treatment with P2Y12 inhibitors (ticagrelor, clopidogrel or&#xD;
        prasugrel)&#xD;
&#xD;
        v. allergy to morphine or paracetamol&#xD;
&#xD;
        vi. patients with recent major bleeding complications or contraindication to dual&#xD;
        antiplatelet therapy:&#xD;
&#xD;
          1. hypersensitivity to aspirin or ticagrelor&#xD;
&#xD;
          2. current use of (new) oral anticoagulation&#xD;
&#xD;
          3. history of bleeding diathesis or known coagulopathy&#xD;
&#xD;
          4. active bleeding&#xD;
&#xD;
          5. refusal of blood transfusions&#xD;
&#xD;
          6. history of intracerebral mass, aneurysm, arteriovenous malformation, or hemorrhagic&#xD;
             stroke&#xD;
&#xD;
          7. known severe liver dysfunction&#xD;
&#xD;
        vii. received any organ transplant or is on a waiting list for any organ transplant&#xD;
&#xD;
        viii. patients undergoing dialysis&#xD;
&#xD;
        ix. pregnant or lactating female&#xD;
&#xD;
        x. patients currently participating in another investigational drug or device study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Isala clinics</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 30, 2017</study_first_submitted>
  <study_first_submitted_qc>January 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2018</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Isala</investigator_affiliation>
    <investigator_full_name>A.H. Tavenier</investigator_full_name>
    <investigator_title>Master of Science</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>July 30, 2021</submitted>
    <returned>August 25, 2021</returned>
    <submitted>August 26, 2021</submitted>
    <returned>September 20, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

